Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated β-blocker treatment;Intérêt de la brimonidine 0,2% dans le traitement du glaucome ou de l'hypertension intraoculaire après intolérance à un traitement par β-bloquant

Journal Francais d'Ophtalmologie

Volumn 25, Issue 6, 2002, Pages 568-575

  Titouamane, S ^a   Baudouin, C ^a  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

Author keywords

Beta blocker; Brimonidine; Primary open angle glaucoma (POAG); Quality of life

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; EYE DROPS;

ADULT; ALLERGIC CONJUNCTIVITIS; ANOREXIA; ARTICLE; ASTHENIA; BIOMICROSCOPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; GLAUCOMA; HEART RATE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MOOD; MULTICENTER STUDY; PATIENT SATISFACTION; QUALITY OF LIFE; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREATMENT PLANNING; VISUAL ACUITY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; APPETITE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; QUINOXALINES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036070760     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Traitement des glaucomes par la brimonidine
2. The effectiveness and safety of brimonidine as mono-, combine or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: A post hoc analysis of an open-label community trial
3. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with β-blockers in glaucoma
4. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjuntherapie to β-blockers in adult patients with glaucoma or hypertension
5. Comparison of the efficacy and safety of latanoprost 0.05% compared to brimonidine 0.2% or dorzolamide 2% when added to topical β-adrenergic blocker in patients with primary open glaucoma or ocular hypertension
6. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce the intraocular pressure
7. An evaluation of the efficacy and quality of life of switching from latanoprost/β-bloquant dual therapy to brimonidine monotherapy
8. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma
9. A comparison of the efficacy, safety, and quality of life of brimonidine with latanoprost versus latanoprost β-blocker
10. Comparison of the clinical success and quality of life impact brimonidine 0.2% and betaxolol 0.25% suspension in patients elevated intraocular pressure
11. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: A randomized clinical Trial
12. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% Suspension in patients with open-angle glaucoma and ocular hypertension
13. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year result in glaucoma patients
14. Twelve-month results of an ongoing randomised trial comparing brimonidine tartrate à 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension
15. Effectiveness and safety of brimonidine as adjunctive therapy patients with elevated intraocular pressure in a large, open-label community trial
16. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: Three-year results
17. Clinical experience with brimonidine 0.2% and Timoptol 0.5% in glaucoma and ocular hypertension
18. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension
19. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
20. The evolving pharmacokinetic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use
21. Personnalités et glaucome chronique
22. A retrospective examination of drug-induced allergy to Alphagan and a proposal for a new reporting system
23. Definitions and conceptual issues
24. Observance thérapeutique et vécu du glaucome prìmìtìf à angle ouvert
25. Improving medication compliance: A randomized clinical trial
26. Intérêt de la mesure de la qualité de vie (QDV) et de l'observance thérapeutique chez les patients atteints de glaucome chronique à angle ouvert
27. Quality of life measures in health care. Design, analysis and interpretation
28. The glaucoma symptom scale
29. Dorzolamide versus pilocarpine as adjunctive therapies to timolol: A comparison of patients preference and impact on daily life
30. Le patient glaucomateux et son traitement: Qu'en est-il réellement?
31. La coopération des malades porteurs d'un glaucome chronique primitif à angle ouvert
32. A miniature compliance monitor for eyedrop medication
33. Questionnaire-based survey on the importance of quality of life measures in ophthalmic practice
34. Health-related quality of life in patients with cataract and glaucoma